Stada and Xbrane Biopharma have chalked up another approval for their Ximluci (ranibizumab) biosimilar, after the UK’s Medicines and Healthcare products Regulatory Agency issued a marketing authorization for the Lucentis rival in Great Britain.
Stada And Xbrane Receive MHRA Nod For Ranibizumab
Ximluci Biosimilar Rival To Lucentis Will Be Launched ‘During 2023’
Stada and Xbrane have celebrated the approval by the UK’s MHRA of the pair’s Ximluci ranibizumab biosimilar rival to Lucentis in Great Britain. A launch is planned this year.
More from Products
More from Generics Bulletin
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.